| 李林子,李昌海,谢雄伟,等.核苷酸切除修复交叉互补组基因 1和人类 X射线交错互补修复基因 1基因多态性与结直肠癌奥沙利铂疗效的相关性[J].安徽医药,2021,25(1):9-12. |
| 核苷酸切除修复交叉互补组基因 1和人类 X射线交错互补修复基因 1基因多态性与结直肠癌奥沙利铂疗效的相关性 |
| Relationship between ERCC1，XRCC1 polymorphism and clinical outcome of patients with advanced colorectal cancer treated with oxaliplatin?based chemotherapy |
| |
| DOI：10.3969/j.issn.1009?6469.2021.01.003. |
| 中文关键词: 结直肠肿瘤 多态性，单核苷酸 奥沙利铂 核苷酸切除修复交叉互补组基因 1(ERCC1) 人类 X射线交错互补修复基因 1(XRCC1) |
| 英文关键词: Colorectal neoplasms Polymorphism,single nucleotide Oxaliplatin Excision repair cross?complementing 1(ERCC1) X?ray repair crosscomplementing gene 1(XRCC1) |
| 基金项目:荆门市科技计划项目(2018YFYB024) |
|
| 摘要点击次数: 1749 |
| 全文下载次数: 682 |
| 中文摘要: |
| 目的探讨核苷酸切除修复交叉互补组基因 1(ERCC1)和人类 X射线交错互补修复基因 1(XRCC1)单核苷酸多态性(SNP)与接受以奥沙利铂为基础的化疗方案治疗晚期结直肠癌(CRC)疗效的关系。方法选取 2017年 11月至 2019年 4月收治于荆门市第一人民医院经病理组织学确诊为晚期直肠癌病人 95例，均接受含奥沙利铂为基础的化疗方案化疗至少 3个周期后评价疗效。采用荧光染色原位杂交测序法对化疗病人外周血中 ERCC1 Asn118Asn、XRCC1 Gln399Arg基因型进行检测，分析各基因型与 CRC病人近期化疗疗效的相关性。结果本研究所选取的病人中各多态性位点的基因型分布均符合 Hardy? Weinberg平衡。病人的性别、年龄、结直肠癌分期(TNM分期)、肿块部位(结肠部位、直肠部位)和含奥沙利铂为基础的化疗方案疗效均差异无统计学意义(P＞0.05)。 95例 CRC病人中，携带 ERCC1 Asn118Asn GG、AG+AA基因型的病人化疗后有效率分别为 51.9%(28/54)和 24.4%(10/41)，ERCC1 Asn118Asn AG+AA基因型病人化疗失败的可能性是 GG型的 3.338倍， OR＝3.338，95%CI为 1.370~8.134，P＜0.05；携带 XRCC1 Gln399Arg CC、TC+TT基因型的病人化疗后有效率分别为 52.0%(26/50)和 26.7%(12/45)，XRCC1 Gln399Arg TC+TT基因型病人化疗失败的可能性是 CC型之间的 2.979倍， OR＝2.979，95% CI为 1.257~7.060，P＜0.05。结论就含奥沙利铂为基础联合化疗失败的可能性而言，携带 ERCC1 Asn118Asn AG+AA基因型比 GG型高；携带 XRCC1 Gln399Arg TC+TT基因型比 CC型高。检测 ERCC1 Asn118Asn和 XRCC1 Gln399Arg单核苷酸多态性可以成为预测结直肠癌病人接受含奥沙利铂为基础的化疗方案疗效的指标。 |
| 英文摘要: |
| Objective To study the relationship between single nucleotide polymorphisms(SNP)in the ERCC1(excision repair cross complementation group 1)， XRCC1(X?ray cross complementing repair gene 1)and clinical outcome of patients with ad? vanced colorectal cancer treated with oxaliplatin?based chemotherapy.Methods A total of 95 patients pathologically diagnosed as advanced colorectal cancer by histopathology admitted to Jingmen NO.1 People’s Hospital from November 2017 to April 2019 werecollected.After all patients received oxaliplatin?based chemotherapy for at least 3 cycles of chemotherapy，the efficacy had been evaluated，also he correlation between each genotype and the short?term efficacy of patients with advanced colorectal cancer hadbeen analyzed.Results(1)The genotype distribution of each polymorphism was found to be of Hardy?Weinberg equilibrium inthe study.There was no significant correlation among gender，age，colorectal cancer stage(TNM stage)，tumor site with chemothera? py efficacy(P＞0.05)(.2)Among the 95 CRC patients，the effective rate of patients with ERCC1 Asn118Asn GG and AG+AA geno? types after chemotherapy was 51.9%(28/54)and 24.4%(10/41)，Patients with XRCC1 Gln399Arg TC+TT genotype were 2.979times more likely to fail chemotherapy than those with CC genotype.OR＝3.338，95% CI:1.370?8.134，P＜0.05；The effective rate of patients with XRCC1 Gln399Arg CC，TC+TT genotypes after chemotherapy was 52.0%(26/50)and 26.7%(12/45)，Patients with TC+TT genotype were 2.979 times more likely to fail chemotherapy than those with CC genotype.OR＝2.979，95%CI:1.257?7.060， P＜0.05. Conclusions In terms of the possibility of failure of oxaliplatin based chemotherapy，the genotype carrying ERCC1 asn118asn Ag + AA was higher than that of GG genotype；the genotype carrying XRCC1 gln399arg TC+TT was higher than CC gen? otype；detection of the single nucleotide polymorphisms of ERCC1 Asn118Asn and XRCC1 Gln399Arg may be used as a predictorof the efficacy of oxaliplatin?based chemotherapy in colorectal cancer patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
